Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

STAT

SEPTEMBER 12, 2024

Moderna said Thursday it would cut its annual spending on research and development by 23%, or $1.1 billion, between 2024 and 2027 in a concession to investors who have viewed the company’s outlays following its pandemic-era windfall as profligate.

Drug Development 297

Drug Development Vaccines 297

European Pharmaceutical Review

APRIL 14, 2023

Oligonucleotide therapeutics represent a relatively novel class of drug, with the potential to modulate drug targets that were previously considered intractable, and with the benefit of fast clinical development times. Success rates in all stages of development is really low. Eight target the liver and four target muscle.

Drug Development 98

Drug Development Vaccines 98

pharmaphorum

JANUARY 18, 2022

million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Smart device developers. Training device developers. Drug developers. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. Medical Device Engineers.

Packaging 52

Packaging Documentation Vaccines Drug Development 52

pharmaphorum

JANUARY 27, 2022

The inaugural LNP Formulation & Process Development Summit is the industry’s first forum dedicated to bringing together drug developers within the LNP field to share the latest scientific breakthroughs on formulation and process development. billion by 2027.

Vaccines 52

Vaccines Drug Development 52

European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. 1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs.

Vaccines 98

Vaccines Immunity Immunization Compounding 98